Why the study?
Does ramipril improve renal outcomes compared to amlodipine in African Americans with hypertensive nephrosclerosis?
Population
1,094 self-identified African Americans with hypertension, aged 18-70 years, nondiabetic, with mild to…
Comparison
Ramipril 2.5-10 mg/day targeted to usual or low… vs Amlodipine 5-10 mg/day targeted to usual or low…
Design
Review, uneven block design with a 2:2:1 ratio for…
Follow-up
median 36 to 37 months
Authors
Loading...
May support ACEI preference for renoprotection in this population; leaves open confirmation in prospective trials.
Does ramipril improve renal outcomes compared to amlodipine in African Americans with hypertensive nephrosclerosis?
In African Americans with hypertensive nephrosclerosis, ramipril provides superior renoprotection and slows disease progression compared to amlodipine.
Sica et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: